Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 313–328 of 328
Study finds daily multivitamin can ease signs of biological aging
A two-year study of 958 adults aged 70+ found that daily multivitamin use slowed biological aging markers measured through epigenetic clocks, with the effect most pronounced in participants showing accelerated aging. While the slowdown was modest—measured in months rather than years—the consistent effect across multiple aging biomarkers suggests multivitamins may influence cellular-level processes relevant to healthspan rather than lifespan extension.
Sleep-based therapy targets glymphatic clearance in neurodegeneration
AstronauTx has secured exclusive global rights to ATX0926, a sleep-based neurological candidate developed through collaboration with Saniona, targeting sleep architecture and glymphatic clearance mechanisms. The approach represents a shift toward using sleep physiology as a therapeutic lever for neurological disease rather than as a symptom to suppress.
Restoring Lysosomal Clearance Targets Parkinson's Root Cause
Researchers identified a protein that restores lysosomal clearance of alpha-synuclein, the pathogenic protein driving Parkinson's disease. This addresses a fundamental breakdown in cellular protein quality control that accelerates neurodegeneration with age.
BioAge advances NLRP3 drug for CVD, retinal care
BioAge is advancing BGE-102, an oral NLRP3 inflammasome inhibitor, into Phase 2 trials for atherosclerotic cardiovascular disease and retinal disease based on Phase 1 data showing tolerability and reductions in inflammatory markers. NLRP3 inhibition represents a mechanistic approach to reducing systemic inflammation implicated in multiple age-related conditions.
Valine Restriction Extends Male Lifespan in Mice
Dietary restriction of valine, a branched-chain amino acid, extends lifespan in male mice and improves healthspan markers in both sexes. The sex-specific lifespan benefit suggests that amino acid metabolism operates through distinct physiological pathways between males and females, with implications for precision nutritional interventions in aging.
AlzeCure completes Phase Ib study of ACD856
AlzeCure completed Phase Ib evaluation of ACD856, a candidate that modulates BDNF and NGF signaling across the blood-brain barrier. Preclinical evidence suggests neuroprotective and anti-inflammatory effects with potential disease-modifying capacity in cognitive decline and depression.
Totus Medicines reports Phase 1a data for TOS-358
TOS-358, a selective mTOR complex 1 inhibitor, demonstrated a 50% clinical benefit rate and 75% disease control rate in Phase 1a testing, with a notably favorable safety profile compared to existing PI3K/AKT/mTOR pathway inhibitors. The compound showed efficacy in patients resistant or intolerant to standard therapies in this class, positioning it as a potential therapeutic option for advanced malignancies.
Cellular silencing bypass extends gene therapy durability
Houdini Bio has developed a machine learning platform that redesigns therapeutic DNA to evade the HUSH complex, a cellular mechanism that silences foreign genetic material. This approach extends gene therapy durability while reducing required doses, with particular relevance for neurodegenerative diseases where sustained expression in long-lived neurons is critical to therapeutic outcome.
Airna doses first patient in Phase 1 trial of AIR-001 for AATD
Airna initiated a Phase 1 trial of AIR-001, an RNA-editing therapeutic designed to correct the genetic mutation underlying alpha-1 antitrypsin deficiency by restoring functional AAT protein production. This approach addresses a monogenic disorder affecting both pulmonary and hepatic function, representing a mechanistic advance in treating a condition with significant longevity impact across multiple organ systems.
Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling
Proteomic analysis identifies distinct and overlapping protein signatures across different manifestations of cerebral small-vessel disease, revealing shared involvement of vascular, immune, and neuronal pathways. Plasma protein panels show predictive capacity for cerebrovascular events, establishing measurable biomarkers for disease stratification and risk assessment.
LanCL1 protein restores cellular repair in neuropathic pain
Lanthionine Synthetase C-Like Protein 1 (LanCL1) has been identified as a therapeutic target for neuropathic pain, with LAT8881 and related Stressed Cell Protectant peptides demonstrating safety and clinically meaningful pain reduction in Phase 1b trials. This mechanism suggests a pathway to address chronic pain through cellular protection and repair rather than traditional analgesic approaches.
Role of Succinate Dehydrogenase in Age‐Related Th17 Inflammation
Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.
Daytime Napping and Mortality Association in Older Adults
Excessive daytime napping—particularly longer duration and morning timing—associates with increased mortality risk in older adults, with effects comparable to accelerated aging. The relationship appears driven by underlying systemic dysfunction rather than sleep disorder alone, making napping patterns a measurable indicator of health status.
Shared neurodegeneration mechanisms reshape Alzheimer's treatment strategy
NeuroSense's Phase 2 data from PrimeC in Alzheimer's disease shows biomarker shifts similar to those observed in prior ALS studies, suggesting neurodegenerative diseases share common biological mechanisms. This finding supports a shift away from single-target drug development toward multi-pathway approaches addressing simultaneous system failures in neurodegeneration.
NLRP3 Inhibition Targets Inflammation Driving Cardiovascular Aging
BioAge Labs has initiated Phase 2 testing of BGE-102, an oral NLRP3 inhibitor designed to reduce cardiovascular risk through suppression of inflammatory pathways. Phase 1 data demonstrated substantial reductions in high-sensitivity C-reactive protein with once-daily dosing, positioning the compound as a candidate for managing systemic inflammation linked to cardiovascular disease progression.
Urinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe
Researchers developed an injectable nanoprobe that detects cellular senescence through urine analysis, using MMP-7 enzyme activity as a measurable marker. This enables non-invasive, real-time monitoring of treatment response in lung cancer and pulmonary disease, establishing a quantifiable method to track senescence burden during therapy.